Publicaciones (148) Publicaciones de SANTIAGO MUÑOZ FERNANDEZ

2024

  1. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

    Journal of Clinical Medicine, Vol. 13, Núm. 5

  2. Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial

    Scientific Reports, Vol. 14, Núm. 1

  3. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

    Medicina Clinica

  4. Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five-Year International Observational Study

    ACR Open Rheumatology, Vol. 6, Núm. 2, pp. 103-110

  5. Raynaud's phenomenon and digital ischaemia induced by ixekizumab

    Rheumatology (Oxford, England), Vol. 63, Núm. 1

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. AB1470 Janus Kinase Inhibitors in Severe Inflammatory Ocular Pathology. Multicenter Study and Literature Review

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1963.2-1964

  3. Biological sequential therapy with rituximab-belimumab in patients with recurrent lupus nephritis

    Reumatologia Clinica

  4. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  5. POS0793-HPR Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 689.2-690

  6. Rápida respuesta a rituximab en un paciente con síndrome antisintetasa asociado a anti-Ro52-Jo1 que debuta con enfermedad intersticial rápidamente progresiva y hemorragia alveolar difusa

    Revista de Patologia Respiratoria, Vol. 26, Núm. 3, pp. 76-79

  7. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477

  8. Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies

    Revista Chilena de Infectologia, Vol. 40, Núm. 6, pp. 618-625

  9. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors

    Vaccines, Vol. 11, Núm. 10

  10. Using natural language processing to explore characteristics and management of patients with axial spondyloarthritis and psoriatic arthritis treated under real-world conditions in Spain: SpAINET study

    Therapeutic Advances in Musculoskeletal Disease, Vol. 15

  11. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2022

  1. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results

    Rheumatology (United Kingdom), Vol. 61, Núm. 8, pp. 3299-3308

  2. Complicaciones de los pacientes con uveítis en un estudio poblacional español: proyecto UveCAM

    Archivos de la Sociedad Española de Oftalmologia, Vol. 97, Núm. 5, pp. 244-250

  3. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 28, Núm. 2, pp. e348-e352

  4. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

    JCR: Journal of Clinical Rheumatology, Vol. 28, Núm. 2, pp. e348-e352